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In this study, diltiazem hydrochloride (DTZ) pellets were prepared successfully by extru-
sionespheronization method. Then methacrylic acid and ethylcellulose coating formula-
tions were employed to make the DTZ pellets sustained release. The pellets with different
coatings were investigated by in vitro dissolution tests. At last, the pellets with the best
coating copolymer were subjected to pharmacokinetic studies in beagle dogs. The disso-
lution profiles of pellets coated with Eudragit NE30D were similar to Herbesser, one of
the marketed sustained release capsules. In the bioavailability study, the principal phar-
macokinetic parameters of self-made pellets and the marketed ones were comparable; the
relative bioavailability of DTZ sustained release capsules compared with Herbesser was
98.5  36.4%. All the data indicated self-made sustained pellets could prolong the release of
DTZ, decrease the fluctuation of drug level in vivo, and increase the compliance of patients.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction multiple administration is approximately 3e5 h. FrequentDiltiazem hydrochloride (DTZ), one member of calcium
channel blockers, is widely used in the treatment of angina
pectoris and hypertension [1]. DTZ is extensively metabolized
by the liver and excreted by the kidney. And it is absorbed
fraction up to about 80%. However, due to an extensive first-
effect, DTZ is subject to an absolute bioavailability of about
40%. The plasma elimination half life following single or, þ86 13898882644 (mobil
. Sun).
g Pharmaceutical Univer
sevier
ang Pharmaceutical Univadministration of immediate release preparations is often
recommended to maintain effective blood plasma levels of
DTZ. A slow and sustained release of the active ingredient is
beneficial to patients to maintain sustainable levels of DTZ in
the blood plasma [2,3].
We aimed to develop sustained release capsules of DTZ in
multiple-unit pellet system (MUS) by extrusionespheronization
method and coating technique. In comparison to thee); fax: þ86 24 23986320.
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some unique advantages. In MUS, pellets are often filled into
hard gelatin capsules or compressed into tablets [4]. In one
single dose of MUS, pellets are rapidly and homogeneously
distributed in the gastrointestinal tract (GIT) in spite of feeding
or fasting condition, thus reduce the risk of high local concen-
tration and side effects, increase the contract region between
drug and the GIT, furthermore, enhance drug absorption and
lower the fluctuations of peak plasma. Therefore, MUS could
decrease dose frequency and increase patient compliance,
improve the safety and efficacy of drug [5e7].
Though there are many approaches to prepare pellets,
such as extrusion and spheronization, fluid bed granulation
[8], centrifugal granulation [9]. Extrusionespheronization is
one of common strategies to prepare pellets for acquiring
modified release systems in pharmaceutical industry since
1970 [10], and the method consists of two basic processes of
extrusion and spheronization. Pellets prepared by themethod
of extrusionespheronization have some advantages, such as
high sphericity, compact structure, low hygroscopicity, nar-
row particle size distribution and smooth surface [11,12].
In thisstudy,weattempt toapplyextrusionespheronization,
simply and easily industrialized preparationmethod to prepare
uncoatedpellets, followedby coating process usingmethacrylic
or ethylcellulose copolymers to achieve the sustained release,
which have the similar pharmacokinetic characteristic to
Herbesser. Herbesser was a commercially available DTZ
sustained release capsules. Many factors have been studied to
adjust the drug release rate by different coating formulations.
The dissolution tests are performed in different media, the
profiles of dissolution from the commercial one and self-made
are compared by similar factors method, and the perfor-
mances in vivo from commercial one and self-made formula-
tion are carried out in beagle dogs.2. Materials and methods
2.1. Materials
Diltiazem hydrochloride was purchased from Nanchong Sci-
ence and Technology Development Co., Ltd (Hubei, China),
Herbesser was purchased from Tianjin Tanabe Seiyaku Co.,
Ltd (Tianjin, China). Huling PH 101 (microcrystalline cellu-
lose) was purchased from Zhanwang Pharmaceutical Co., Ltd
(Zhejiang, China). Eudragit NE30D, Eudragit RS30D and
Surelease were kindly provided by Colorcon (Shanghai,
China). HPLC-grade methanol and acetonitrile were pur-
chased from Fisher Scientific (Pittsburgh, PA, USA). All other
materials were of analytical grade and used as received.
2.2. Preparation of diltiazem hydrochloride (DTZ)
sustained release pellets
Drug-loaded pellets were prepared by the extrusione-
spheronization method. The formulation of the cores was as
follows: DTZ 125 g; MCC 125 g; HPMC (K4M, 2%) 110 ml, which
was used as a binder. The powders were mixed for 30 min
before the adhesive was added, then appropriate quantity of
binder was added slowly during constant mixing, and theprocess continued for a further 20 min. The wet mass was
extruded at room temperature, through a die of 0.8 mm
diameter and 4 mm in length by 20 rpm equipped with an
axial screen extruder (WL350,Wenzhou, China), the extrudate
was collected in a container before it was spheronized. About
50 g of extrudate was spheronized at a time, on a spheronizer
40 cm in diameter equipped with a grooved plate, for 2 and
10 min at 2000 and 8000 rpm, respectively. The pellets were
dried under conditions at 40  2 C for 24 h. The 18e24 mesh
pellets were chosen for coating.
Eudragit NE30D, Eudragit RS30D and Surelease, three
types of aqueous polymeric dispersions, were used for the
preparation of sustained release pellets. The formulations
were followed as:
Formulation 1 (F1): coated with Eudragit NE30D, resulting
in 6e13% coat loading. Coating suspension includes talc,
HPMC (E5) and SDS.
Formulation 2 (F2): coated with Eudragit RS30D, resulting
in 10e25% coat loading. Coating suspension includes talc, TEC
and SDS.
Formulation 3 (F3): Surelease, resulting in 10e30% coat
loading.
A fluid-bed bottom spray processor was adopted for the
coating of the pellets by using Eudragit NE30D or Eudragit
RS30D as the coating solution. The coating suspensions were
prepared as follows steps: (1) Eudragit NE30D or Eudragit
RS30D was dripped into the desired volumes of water and
agitated by magnetic stirrer at room temperature for at least
30 min; (2) micronized talc was dispersed in water and stirred
until no lumps formed; (3) materials (1) and (2) were mixed
and stirred, then the HPMC/TEC, SDS were also added into the
suspensions. After stirred for at least 1 h, the coating sus-
pensions were spraying onto the pellets. After Surelease
dispersed in water 1 h, the solutions were spraying onto the
pellets.
Coating conditions: inlet temperature: 30 C, outlet tem-
perature: 25e30 C, spray rate: 2ml/min, atomization pressure
is 0.2 MPa, blast pressure is 0.3 MPa. The final pellets were
dried in oven at 40 C for 12 h.2.3. Assay of the drug content
Drug content was determined by the HPLC method. The HPLC
system included a LC-AT pump and SPD-10A UVeVis detector
(SHIMADZU Japan). A Kromasil C18 column (5 mm,
200  4.6 mm) was used. The mobile phase consisted of so-
dium acetateecamphor sulfonic acid buffer (dissolve 9.0 g of
sodium acetate and 1.2 g of camphor sulfuric acid in 500 ml of
water)eacetonitrileemethanol (50:26:24, V/V/V), adjust the pH
value to 6.5 with acetic acid, the flow rate was 1.0 ml/min, and
the UV detector was set at 240 nm.
From each batch of the coated pellets, a certain amount
was taken and milled to fine powders. Then fine powders
containing 100 mg drug were weighed and added to a 100 ml
volumetric flask containing 70ml ofmethanol. After, a 30-min
ultrasonic extraction, the solution was diluted with methanol
to 100 ml and then filtered through a 0.45 mm membrane.
Precisely 5 ml of this solution was transferred to 25 ml volu-
metric flask and methanol was added to give a volume of
Table 1 e Formulation of uncoated pellets containing different amounts of MCC.
Uncoated pellets 1 2 3 4 5
DTZ (%) 30 40 50 60 80
MCC (%) 70 60 50 40 20
Binder HPMC (2%) HPMC (2%) HPMC (2%) HPMC (2%) HPMC (2%)
Angles of repose (q) 16  1 16  1 17  2 25  3 40  2
1 h dissolution (%) 100.12  5.36 101.02  1.46 99.21  4.94 99.93  4.12 101.23  1.68
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Fig. 1 e In vitro release profiles of DTZ from the uncoated
pellets in water at 1 h (each point represents the
mean ± SD, n ‡ 3).
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samples were analyzed in triplicate.
2.4. In vitro dissolution tests
The release of diltiazem hydrochloride (DTZ) from pellets was
investigated based on ChP 2010 Type 2 dissolution apparatus
(paddle method) and all the release tests were conducted in
triplicate. In this case, the 900 ml medium was kept at
37  0.5 C and the rotating speed was 100 rpm. 0.1 M HCl so-
lution, pH 4.5 sodium acetate buffer, pH 6.8 and pH 7.2 phos-
phate buffers, and purified water were used as dissolution
media. The capsules containing the drug pellets equivalent to
90 mg DTZ were used in all dissolution tests. At each pre-
determined time point, a 5 ml aliquot of dissolution medium
was withdrawn and replaced by the same volume of fresh
medium. The total volume of mediumwas kept at 900ml. The
sample solution was filtered through 0.45 mm filtration mem-
brane and analyzed using a UV spectrophotometer (Beijing
Rayleigh Analytical Instrument Co.) at 240 nm.
2.5. Bioavailability studies
2.5.1. In vivo studies
The sustained pellets of DTZ were filled into hard gelatin cap-
sules for the pharmacokinetic parameters studies. Meanwhile,
Herbesser was served as the control. The experimental pro-
tocol was admitted by the university ethics committee for the
use of experimental animals and conformed to the guideline for
care and use of laboratory animals. The study was based on
single-dose, open-label, randomized two-way crossover design
with wash out period of one week. The six male beagle dogs
were divided into 2 groups. After 12 h of fasting, 90 mg of DTZ
test and reference preparationswere orally administered to test
and reference group dogs under fasted conditions, respectively.
Venous blood samples (5ml) were collected 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 12, 24 and 36 h after dosing and immediately centrifuged.
Plasma samples were kept frozen at 20 C until assay. Diltia-
zem hydrochloride in plasma was determined using liquid
chromatographyetandemmass spectrometry (LCeMS/MS).
100 ml of plasma was mixed with 50 ml of internal standard
(verapamil solution) and 50 ml of mobile phase solution. The
solution vortexed for 1 min, 100 ml of acetonitrile added to
precipitate the proteins in the plasma. After centrifugation
(10,000 rpm) for 10 min, 5 ml aliquot of supernatant was
directly injected into the high performance liquid chroma-
tography system.
Chromatographic conditions [13]: ACQUITY UPLCTMBEH
C18 column (1.7 mm, 50 mm  2.1 mm, Waters Corp, Milford,
MA, USA); mobile phase consisted of acetonitrile: 8 mMammonium acetate (70:30, v/v); flow rate 0.2 ml/min; UV de-
tector wave length 240 nm.
2.5.2. Data analysis
The concentrations of DTZ in plasma were calculated, and all
the data were processed by DAS 2.0 statistical software. The
area under themean plasma concentrationetime curves from
zero to time (AUC0e36 h) and (AUC0eN) was calculated.3. Results and discussion
In this study, DTZ sustained release pellets were prepared by
the extrusion/spheronization method, and then were sub-
jected to coating with methacrylic acid copolymers (Eudragit
NE30 or Eudragit RS30) or derivative of ethylcellulose (Sure-
lease). The in vitro release studies showed that the dissolution
profiles of the pellets coated with Eudragit NE30Dwere similar
to the commercially available DTZ sustained release capsules.
In vivo study, the principal pharmaceutical parameters
showed that the profiles of DTZ from self-made and the
marketed one were comparable.
3.1. Formulation and process parameters optimization
3.1.1. Effect of amount of MCC
Formulations of the uncoated pellets are described in Table 1
and the release profile of DTZ in water in 1 h is shown in
Fig. 1. The drug release behavior was similar from different
formulations. At 5 min, the accumulative release of the un-
coated pellets was about 80% and reached 100% at 20min. That
is to say, DTZ could be completely released from the uncoated
Table 2 e The effect of disc speed on pellet physical characteristics.
Disc speed (rpm) 1000 2000 5000 8000 10,000
18e24 mesh cut yield (%) 74  2.3 84  4.3 87  4.1 87  3.3 76  1.3
Roundness 2 4 4 4 4
Sphericity (q) 40.2  1.3 22.3  2.5 24.5  3.6 23.3  4.3 24.6  2.7
Bulk density (g/ml) 0.77  0.1 0.79  0.3 0.81  0.2 0.82  0.1 0.81  0.2
Friability (%) 0.43  0.11 0.45  0.12 0.46  0.12 0.43  0.1 0.45  0.1
Table 3 e Analog analysis of the home-made sustained
release capsules and reference capsules in different
media (n ‡ 3).
Medium f2
Water 72  2
pH 1.0 67  3
pH 4.5 68  4
pH 6.8 66  2
pH 7.2 68  3
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includesDTZ andmicrocrystalline cellulose (MCC).MCC acts as
fillers and disintegrants enhancing the dissolution rates of the
pellets. In addition, the solubility of diltiazemHCl is 565 mg/ml
in water, indicating dissolution of the drug is not limit by solu-
bility [14].MCCnotonlyplaysan important role in theprocessof
disintegration, but also influences the process of granulation.
Probably acting as “molecular sponge” [15] and “crystallite-gel”
[16], MCC is considered as one of the most common extru-
sionespheronization ingredients, making the pellets with such
desirable characteristics as good sphericity, low friability, nar-
row particle size distribution and smooth surface properties.
Whendrug-loadingwas 80%, the angle of reposewas about 40,
and pellets were highly friable with irregular shapes like dumb-
bell and short bar. However, when drug-loading was 30%, the
angle of repose was about 16, and pellets were extremely
flexible with a good sphericity. Given that only the difference
among C1eC5 formulation was the amount of MCC, the results
suggested that the amount ratio between drug and MCC had a
significant effect on the process of extrusion and spheroniza-
tion. Inorder toget thedesirabledrug-loadingandgoodphysical
characteristics of pellets, we chose uncoated-pellets drug-
loading was 50%.
3.1.2. Influence of rotational speed
The method of extrusion/spheronization consists of five
procedures: preparation the damp mass-wet granulation;
screening the wetmass into cylinders e extrusion; breaking up
the extrudate and rounding off the particles into spheres e
spheronization; drying the pellets [17]. Some process parame-
ters influence the morphologic characteristic and rheological
parameters of the pellets. For example, high concentration of
adhesive (5%, HPMC) resulted in severely overwetted masses
that could not be extruded or spheronized. By Contrast, low
concentration of adhesive (1%, HPMC) led to dry masses which
could not be extruded. Among five procedures, we particularly
investigated the rotational speed of disc effect on the physical
characteristic of pellets, including shape of pellets, hardness,
size, sphericity, porosity of pellets. When the rotational speed
was low, most of pellets were short cylindrical resulting from
the minor shearing force which leads to breaking short cylin-
drical into the compact breads. In comparison, when the rota-
tional speed was high, the centrifugal force made the pellet
cracking resulting of the formation of powders, as well as the
adhesions of pellets bringing about wide size distribution. As
shown in Table 2, it can be seen that different rotational speeds
had notable influence the morphologic characteristic and size
distributionofpellets.When the rotational speedwas1000 rpm,
the pellets were dumb-bell, low fluidity. When the rotational
speedrangedfrom2000to10,000rpm,18e24meshcutyieldwashigher than 80%, highfluidity, narrow size distribution. In order
to get desirable characteristic of pellets, we chose rotational
speed 2000 rpm for 2 min to cut off the extrudate, and then the
speed rose up to 8000 rpm gradually, which was continued
10min to get the final pellets.
3.1.3. Influence of different coating formulations
The profiles of DTZ released from the sustained pellets with
different coating formulation in water are shown in Fig. 2, and
it can be seen from Fig. 2 that different coating formulations
and coating weight gains had a significant influence of the
release of DTZ from the coated pellets. In general, Eudragit
NE30D and Eudragit RS30D coating suspension successfully
prolonged the release in water, however, the coating of
Surelease did not properly control the dissolution and more
than 40% of drug-loading was released in 2 h. Even with 30%
coating weight gain, DTZ was released about 50% in 2 h, 20%
higher than that of Herbesser. Therefore, the coating poly-
mers of Eudragit NE30D and Eudragit RS30D were better for
prolonging the release of DTZ.
Coatingweight gain had a significant effect on DTZ release.
Clearly, with higher coating weight gain, the DTZ pellets
showed slower release rate. For coatingwith EudragitNE30D,
when coat-loading was about 12.5%, only 80% of DTZ was
released from the pellets at 24 h. Compared to the coating level
of 6.5%,more than 80% of drugwas released at 5 h. The release
profiles of pellets coated by Eudragit NE30D and Eudragit
RS30D, respectively, were comparable. When comparing
Fig. 2A and B, it was found that 8.5% coating weight gain of
Eudragit NE30D and 15% coating weight gain of Eudragit
RS30D were better similar to Herbesser. But for Eudragit
RS30D, the release rate of DTZ from 15% coat-loading was
faster than Herbesser, and nearly 70% of DTZ was released
from the pellets at 5 h. When increasing the coating weight
gain to 20%, nearly 55% of DTZwas released from the pellets at
5 h. When the coating weight gain was 8.5%, the accumulative
release percent of DTZ from the pellets coated with Eudragit
NE30D was nearly 60%, very similar to the release rate of
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Fig. 2 e Release profiles from the coated pellets with different coating polymers and coating weight gains. (A) Eudragit
NE30D (B) Eudragit RS30D (C) Surelease, H-Herbesser (each point represents the mean ± SD, n ‡ 3).
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stage of the dissolution, we chose Eudragit NE30D as the
coating polymer, coatweight gain of 8.5%, and the final coating
formulation included sodium dodecylsulfate (1% of Eudragit
RS30D, w/w) as antistatic agents and talc (20% of Eudragit
RS30D, w/w) as antiadherent.
3.2. Drug release comparison
Dissolution profiles of home-made preparations and mar-
keted sustained-release capsules were compared in variousmedia, including 0.1 M HCl, pH 4.5 NaAceHAc buffers, water,
pH 6.8 and pH 7.2 phosphate buffer solutions. The dissolution
profiles of self-made pellets and Herbesser are shown in
Fig. 3. From the dissolution results, the self-made pellets
shown slower release rates than that of the marketed ones in
0.1 M HCl and pH 4.5 NaAceHAc buffer solution, while in the
higher pH such as pH 6.8 and pH 7.2 phosphate buffer solu-
tions, the different release rates were present. In general,
there were nearly no various profiles of dissolution from the
self-made pellets in various media, resulting from the non-
sensitive to pH of Eudragit NE30D.
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market formulation and self-made preparing are presented in
Table 3. Similar index was calculated by the similarity factor
(f2) [18]:
f2 ¼ 50 log
("
1þ 1
n

Xn
t¼1
ðRt TtÞ2
#0:5
 100
)
where n is the number of dissolution sample, and Rt and Tt are
the percentages of the Herbesser and self-made pellets drug
release, respectively. The valve of f2 value is between 0 and
100. If f2 of control and test preparation is between 50 and 100,
then these two preparations drug release are similar. From the
data of Table 3, the results of f2 in different medium were all
more than 50, indicating that self-made sustained release
pellets and Herbesser have similar drug release profiles.
3.3. Drug release mechanism
The drug-release data was fitted according to differentmodels
in attempt to elucidate the release mechanism. The kineticTable 4 e Models for drug release fitting and correlation
coefficients.
Model Equation r
Zero-order model Qt ¼ 8.1736 þ 8.8219t 0.9620
First-order model ln(100  Qt) ¼ 0.1855t þ 4.6067 0.9970
Higuchi Qt ¼ 33.571t1/2  16.847 0.9910
RitgerePeppas log Qt ¼ 0.7228log t þ 1.2703 0.9827models consist of zero order [19], first order [20], Higuchi
model [21] and RitgerePeppasmodel [22]. The optimumvalues
for the parameters present in each equation were determined
by linear or non-linear least-squares fitting methods. As
shown in Table 4, the first-order model was best fitted for the
home-made sustained release pellets.
Manymodesof drug release fromtheextend-control pellets
were first-order model, which releases the drug from the
dosage form at the constant rate, reducing the fluctuation of
drug level in theblood,maintainbloodconcentrationof drugat0.00 
20.00 Pl
as
m
a
Time (h)
Fig. 4 e Average diltiazem plasma concentrationetime
curves of the reference and test capsules (each point
represents the mean ± SD of 6 dogs).
Table 5 e Pharmacokinetic parameters of test and reference preparations.
T1/2 (h) Cmax (ng/ml) Tmax (h) AUC0e36 (ng h/ml) AUC0eN (ng h/ml)
Reference 4.2  1.9 85.0  55.1 4.5  1.9 761.1  528.4 767.3  535.5
Test 4.9  1.9 100.0  66.4 3.5  0.8 824.9  523.6 838.4  601.2
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order drug release profiles, different technologies can be used,
such as, hydrophilic or matrix systems with channel forming
agents and barrier membrane coated multiparticulate sys-
tems. Eudragit NE30D was one of low permeability, pH inde-
pendent swelling coating polymers. It was assumed that some
drives, as follows, to obtain the first order drug release profiles
for EudragitNE30D: (1) Concentration gradient. Once the film
was in contact with water, the film swelled, and water slowly
permeated into the core of pellets, and the drugwas dissolved,
thus, the saturable solution of drugs within the coating. Drug
molecules diffused down the concentration gradient, and
finally released into the outer medium. (2) Channel effect. The
influxwater induced swelling ofmembrane and expanded the
copolymer network; the compact membrane was converting
into un-continuous one, leading to the pore for the water
molecule and drug molecule freely influx and efflux the pellet
film. In addition, a number of aqueous channels were formed
across the film once the pellets are in contact with water, and
acted as the release gate for the drug.
3.4. Bioavailability
The in vivo pharmacokinetic behavior of self-made sustained
and commercial available capsules (Herbesser) were inves-
tigated following oral administration of 90 mg of DTZ to six
healthy beagle dogs. Mean plasma concentrationetime curves
after administration of test and control preparation were
shown in Fig. 4. There main bioavailability parameters are
listed in Table 5. Themean relative bioavailability of DTZ self-
made sustained pellets to Herbesser, which was calculated
from the AUC0e36 of DTZ, was 98.5  36.4%. The average peak
concentration (Cmax) of the reference (85.0  55.1 ng/ml) was
slightly lower than that of the test (100.0  66.4 ng/ml),
AUC0eN of test and reference were 767.3  535.5 ng h/ml, and
838.4  601.2 ng h/ml, respectively. From the data of main
bioavailability parameters, it could conclude that the phar-
macokinetic profiles of self-made pellets and marketed ones
in vivo were comparable.4. Conclusion
The DTZ sustained release pellets were successful prepared.
The formulation of the uncoated pellets included MCC,
binders and DTZ. The uncoated pellets achieved good sphe-
ricity, low friability, narrow particle size distribution and
smooth surface. It was found that the rotational speed has a
significant effect on the physic characteristics of pellets pre-
pared by extrusion and spheronization method. The coating
polymer Eudragit RS30D and coating weight gain 8.5% could
prepare the desired DTZ sustained-release pellets, which had
similar release profiles to the marketed Herbesser with f2more than 60. From the bioavailability studies, it was obvious
that the home-made sustained pellets could prolong the
release of DTZ and has comparable in vivo pharmacokinetic
performance to the marketed Herbesser.r e f e r e n c e s
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